Masked il-12 cytokines and their cleavage products
Engineered IL-12 cytokines with protease-activated masking portions address the short half-life and systemic side effects of traditional cytokines, providing targeted and effective cancer therapy.
TW202626697APending Publication Date: 2026-07-01XILIO DEVELOPMENT INC
0 Cites 0 Cited by
Patent Information
- Application Number
- TW114143243
- Authority / Receiving Office
- TW · TW
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-12-18
- Filing Date
- 2021-03-31
- Publication Date
- 2026-07-01
AI Technical Summary
Technical Problem
Cytokines, such as IL-12, have a short half-life and cause adverse health effects due to systemic immune activation when administered, necessitating frequent dosing and posing risks.
Method used
Engineered IL-12 cytokines with a masking portion at receptor binding sites, activated by proteases at target sites, allowing localized activation and reduced systemic immune response.
Benefits of technology
Enhances tumor-specific cytokine activity with reduced systemic side effects, enabling effective cancer treatment with prolonged half-life and targeted delivery.
✦ Generated by Eureka AI based on patent content.
Abstract
The present invention relates to masked IL-12 cytokines, comprising an IL-12 cytokine or functional fragment thereof, a masking moiety and a proteolytically cleavable linker. The masking moiety masks the IL-12 cytokine or functional fragment thereof thereby reducing or preventing binding of the IL-cytokine or functional fragment thereof to its cognate receptor, but upon proteolytic cleavage of the cleavable linker at a target site, the IL-12 cytokine or functional fragment thereof becomes activated, which renders it capable or more capable of binding to its cognate receptor.
Need to check novelty before this filing date? Find Prior Art